Overview & Therapeutic Approach
Ataxia encompasses neurodegenerative conditions affecting the cerebellum and spinal tracts, impairing balance, fine motor skills, and speech. Our partner centers evaluate patients for investigational mesenchymal stem cell (MSC) infusions combined with structured neuro-rehabilitation.
Scientific Basis: Investigated for paracrine signaling, down-regulation of neuroinflammatory pathways, and secretion of neurotrophic factors in cellular models.
Regulatory Transparency Notice
Regulatory Classification: Cell therapy for Ataxia is strictly investigational/experimental under ICMR 2017/2021 guidelines and CDSCO directives. It is conducted solely under Institutional Ethics Committee (IEC) review and clinical trial monitoring, not as standard-of-care medicine.
Candidacy & Preliminary Evaluation
Eligibility is determined via a multi-specialist medical board review of diagnostic records prior to international travel:
✓ Eligible Indications
Eligible Conditions: Autosomal dominant spinocerebellar ataxias (SCA 1, 2, 3, 6, etc.), Friedreich’s Ataxia (FRDA), and Idiopathic Late-Onset Cerebellar Ataxia (ILOCA).
• Clinical Criteria
Clinical Criteria: Confirmed genetic testing/repeat expansion panels, recent brain/spine MRI, baseline Scale for the Assessment and Rating of Ataxia (SARA) score, and cardiology clearance.
✗ Exclusion Criteria
Exclusions: Advanced cardiomyopathy (EF < 40%), active systemic infection, tracheostomy dependence, severe unmanaged dysphagia with recurrent aspiration pneumonia, or active malignancies.
Potential Functional Outcomes & Response Variability
Therapy results are non-guaranteed and highly variable. Clinical studies indicate that outcomes range from minor functional gains to disease stabilization, while a subset of patients may experience no therapeutic response.
Why Select Our Medical Center in India?
• Hospital Accreditation
Hospital Accreditation: Interventions take place in JCI- and NABH-accredited tertiary care hospitals with 24/7 critical care infrastructure.
• cGMP Cleanroom Processing
cGMP-Certified Processing: Cells processed in ISO Class 5 cleanrooms with mandatory viability testing, flow cytometry profiling, and sterility/endotoxin release certificates.
• Multidisciplinary Oversight
Supervised Clinical Care: Dedicated neuro-rehabilitation teams, certified neurologists, and cellular biologists.
• Cost Efficiency
Financial Transparency: Fixed, itemized packages at lower cost than private European or Latin American clinics, with no hidden hospital fees.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted intrathecal lumbar puncture + IV cellular therapy, SARA neurological assessments, and motor rehabilitation).
(Administered via Intrathecal (Lumbar Puncture) + Targeted IV under strict cGMP lab standards).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
International Patient Services
Logistics & Accommodation
Typical Treatment Protocol (7–10 Days)
Source Distinctions, Quality Rigor & Safety Profile
Full procedural transparency requires informing patients of risks and therapeutic limits:
Autologous Cells
Autologous Cells: Harvested from the patient’s own bone marrow or adipose tissue; eliminates foreign immunological reactions but requires an invasive collection procedure.
Allogeneic Umbilical Cord Tissue
Allogeneic Umbilical Cord Tissue: Screened donor tissue processed in ISO Class 5 cleanrooms.
Mandatory Donor Safety Testing
Mandatory Donor Safety Testing: Every donor batch undergoes mandatory molecular screening for HIV 1 & 2, Hepatitis B (HBV), Hepatitis C (HCV), Syphilis (VDRL), Cytomegalovirus (CMV), and Human T-lymphotropic virus (HTLV 1/2).
Cellular Quality Release Standards
Cellular Quality Release: Documented post-thaw viability exceeding 90%, sterility cultures (zero bacterial/fungal growth), and negative endotoxin testing (LAL test).
Short-Term Adverse Events
Short-Term Adverse Events: Transient post-procedure headache, low-grade fever, lumbar/injection site discomfort, lightheadedness, or mild nausea.
Inherent Risks & Mitigation
Inherent Risks: Infection risk, bleeding, or rare allergic reactions to carrier solutions, mitigated through certified cGMP cleanrooms and sterile hospital theater settings.
Biological Reality & Non-Cure Notice
Biological Reality: Stem cells do not repair mutated genes (such as FXN or ATXN repeats) and cannot regenerate dead, fibrosed cerebellar neurons. Therapy is not a cure.
Frequently Asked Questions: Ataxia Care
Evidence-based clinical guidance regarding cellular protocols, anticipated outcomes, and international logistics
Stem cell therapy is an investigational cytoprotective treatment rather than a genetic cure. Its primary clinical objective is to decelerate neurodegeneration, protect surviving Purkinje neurons, and stabilize motor coordination scores (Dong et al., 2018).
Protocols evaluate Spinocerebellar Ataxia (SCA types 1, 2, 3, 6), Friedreich's Ataxia, Idiopathic Cerebellar Ataxia, and Secondary Cerebellar Atrophy in patients who remain ambulatory or semi-ambulatory.
Clinical teams monitor improvements using the Scale for the Assessment and Rating of Ataxia (SARA), tracking gait stability, speech dysarthria clarity, finger-to-nose dysmetria, and reduction in postural tremors.
Delivery utilizes targeted intrathecal lumbar puncture into the cerebrospinal fluid (CSF) under local anesthesia, allowing direct subarachnoid transport across the blood-brain barrier to cerebellar tissues, paired with systemic IV infusion.
Yes. Combining cellular therapy with specialized vestibular rehabilitation, balance training, and gait physiotherapy accelerates neuroplastic synaptic reconnection and optimizes functional outcomes.
The standard stay is 4 to 5 days, covering high-resolution 3T brain MRI scans, comprehensive neurological SARA scoring, cellular administration, post-procedure observation, and fit-to-fly clearance.
Peer-Reviewed Scientific Citations & Clinical References
Key published clinical trials and peer-reviewed literature supporting cellular therapy in Ataxia: